SOURCE: UV Flu Technologies, Inc.
CENTERVILLE, MA–(Marketwire – August 5, 2010) – UV Flu Technologies, Inc. (
M.A.R.C. is one of the finest medical technology training facilities in the country, offering world class surgical training for a variety of specialties. It is one of the few places in the country offering as many as forty, state-of-the art bio skill lab stations in a hospital style setting alongside custom designed conference and lecture facilities delivering full videoconferencing in a dedicated facility. The introduction of new technologies and medical devices requires constantly evolving expertise and the centre offers training to a huge and skilled market of medical specialists encompassing North, Central and South America, as well as the Caribbean.
“This order is significant when you consider the client’s needs and perspective,” stated Jack Lennon, President of UV Flu Technologies. “They are an internationally-respected medical facility that instructs a diverse client list of doctors, surgeons and other talented practitioners of the medical profession from throughout the western hemisphere.”
“We trust that other teaching facilities, at home and abroad, will take note and quickly identify that our product offers a cost effective and easy to implement method to increase the overall safety level of any facility by immediately lessening the risk of airborne bacteria, and one that also limits the spread of noxious odors and Volatile Organic Compounds (‘VOC’),” said Mr. Lennon, as he further comments, “The ViraTech UV-400 is specifically designed to kill dangerous strains of bacteria which may present themselves from time to time, while also reducing the levels of other contaminants and odors from the air we breathe.”
Mr. Lennon concluded by saying, “Here is a sale which clearly demonstrates product penetration into a massive market encompassing all forms of medical teaching facilities, as well as businesses such as funeral homes and working pathology labs worldwide. The potential list of users in this sector is huge.”
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.
About UV Flu Technologies, Inc. (
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
Email Contact
Click here to see all recent news from this company